Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADIPOR1
REST API REST API
Homo sapiens
ADIPOR1 is differentially expressed in 213 experiments: 70 organism parts: bone marrow, placenta, ... (68 more);, 142 disease states: normal, breast carcinoma, ... (140 more);, 63 cell types 316 cell lines 25 compound treatments and 69 other conditions.
Synonyms ACDCR1, PAQR1
Orthologs IZH2 (Saccharomyces cerevisiae)   ADIPOR1 (Gallus gallus)   IZH1 (Saccharomyces cerevisiae)   Adipor1 (Mus musculus)   Adipor1 (Rattus norvegicus)   Q3T0U4_BOVIN (Bos taurus)   adipor1b (Danio rerio)   adipor1a (Danio rerio)   ENSCING00000013470 (Ciona intestinalis)   CG5315 (Drosophila melanogaster)   adipor1 (Xenopus laevis)   ADIPOR1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, hormone binding, hormone-mediated signaling pathway, fatty acid oxidation, identical protein binding, lipid metabolic process, protein kinase binding, protein heterodimerization activity, receptor activity, integral to membrane
InterPro Term HlyIII-related
UniProt Accession C9J0W7, C9JNM5, Q96A54, F8W782
Search EB-eye ENSG00000159346
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-1577, E-MTAB-24, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (30 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA468
2
E-MTAB-62, E-MEXP-440
MRC5
1
E-MTAB-62
NA18516
1
E-GEOD-19480
ssMCF7
1
E-GEOD-5258
310 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-20677, E-GEOD-4219, ... (36 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
epithelial cell
1
2
E-MEXP-2034, E-GEOD-4483, E-GEOD-10797
vascular smooth muscle cell
1
E-TABM-130
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
57 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-1577, ... (43 experiments)

Factor Value U/D Experiments
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MEXP-231
multiple myeloma
2
E-GEOD-6691, E-MTAB-62
liver carcinoma
1
E-MTAB-37
colorectal cancer
1
E-GEOD-15960
epilepsy
1
E-GEOD-4290
136 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5824, E-TABM-868, E-GEOD-5099, E-MEXP-1958, ... (16 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
granulocyte-colony stimulating factor
1
E-GEOD-7400
ethanol
1
E-MEXP-2241
Cxcl12
1
E-GEOD-7307
control - keratinocyte growth factor
1
E-GEOD-7216
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-2666, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-21138, E-GEOD-19665

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-21750, E-GEOD-22593, E-TABM-601, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1273

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-16363, E-GEOD-20876, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.324 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM